Research programme: Hydroxy bupropion - Sepracor
Latest Information Update: 31 Aug 2006
At a glance
- Originator Sepracor
- Class
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Major depressive disorder
Most Recent Events
- 31 Aug 2006 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
- 31 Aug 2006 Discontinued - Preclinical for Depression in USA (unspecified route)
- 18 Apr 2001 Preclinical development for Attention-deficit hyperactivity disorder in USA (Unknown route)